Drug Profile
Moxifloxacin ophthalmic solution - Zion Therapeutics
Alternative Names: ZimoxinLatest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator Zion Therapeutics
- Class Antibacterials; Azabicyclo compounds; Cyclopropanes; Fluoroquinolones; Piperidines; Pyrrolidines; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Endophthalmitis
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for clinical-Phase-Unknown development in Endophthalmitis(Prevention) in USA (Intraocular, Injection)
- 22 Aug 2017 Chemical structure information added
- 07 Aug 2017 Zion Therapeutics plans a phase II/III trial for Endophthalmitis (Prevention) in USA (Intracameral, Injection) (NCT03244072)